CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION & SCOPE
1.2. SEGMENT DEFINITIONS
1.2.1. DRUG CLASS
1.2.2. TRANSPLANT TYPE
1.3. ESTIMATES AND FORECAST TIMELINE
1.4. RESEARCH METHODOLOGY
1.5. INFORMATION PROCUREMENT
1.5.1. PURCHASED DATABASE
1.5.2. GVR’S INTERNAL DATABASE
1.5.3. SECONDARY SOURCES
1.5.4. PRIMARY RESEARCH
1.6. INFORMATION ANALYSIS
1.6.1. DATA ANALYSIS MODELS
1.7. MARKET FORMULATION & DATA VISUALIZATION
1.8. MODEL DETAILS
1.8.1. COMMODITY FLOW ANALYSIS
1.9. LIST OF SECONDARY SOURCES
1.10. OBJECTIVES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT
2.2. SEGMENT SNAPSHOT
2.3. COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET VARIABLES, TRENDS, & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.2. MARKET DYNAMICS
3.2.1. MARKET DRIVER ANALYSIS
3.2.2. MARKET RESTRAINT ANALYSIS
3.3. BUSINESS ENVIRONMENT ANALYSIS
3.3.1. INDUSTRY ANALYSIS - PORTER’S FIVE FORCES ANALYSIS
3.3.1.1. SUPPLIER POWER
3.3.1.2. BUYER POWER
3.3.1.3. SUBSTITUTION THREAT
3.3.1.4. THREAT OF NEW ENTRANTS
3.3.1.5. COMPETITIVE RIVALRY
3.3.2. PESTLE ANALYSIS
CHAPTER 4. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: DRUG CLASS BUSINESS ANALYSIS
4.1. DRUG CLASS MARKET SHARE, 2024 & 2033
4.2. DRUG CLASS SEGMENT DASHBOARD
4.3. MARKET SIZE & FORECASTS AND TREND ANALYSIS, BY DRUG CLASS, 2025 TO 2033
4.4. CALCINEURIN INHIBITORS
4.4.1. CALCINEURIN INHIBITORS MARKET,
4.5. ANTIPROLIFERATIVE AGENTS
4.5.1. ANTIPROLIFERATIVE AGENTS MARKET,
4.6. MTOR INHIBITOR
4.6.1. MTOR INHIBITOR MARKET,
4.7. STEROIDS
4.7.1. STEROIDS MARKET,
4.8. OTHER DRUG CLASSES
4.8.1. OTHER DRUG CLASSES MARKET,
CHAPTER 5. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: TRANSPLANT TYPE BUSINESS ANALYSIS
5.1. TRANSPLANT TYPE MARKET SHARE, 2024 & 2033
5.2. TRANSPLANT TYPE SEGMENT DASHBOARD
5.3. MARKET SIZE & FORECASTS AND TREND ANALYSIS, BY TRANSPLANT TYPE, 2025 TO 2033
5.4. KIDNEY
5.4.1. KIDNEY MARKET,
5.5. LIVER
5.5.1. LIVER MARKET,
5.6. HEART
5.6.1. HEART MARKET,
5.7. LUNG
5.7.1. LUNG MARKET,
5.8. PANCREAS
5.8.1. PANCREAS MARKET,
5.9. OTHER TRANSPLANT TYPES
5.9.1. OTHER TRANSPLANT TYPES MARKET,
CHAPTER 6. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS AND TRANSPLANT TYPE
6.1. REGIONAL MARKET SHARE ANALYSIS, 2024 & 2033
6.2. REGIONAL MARKET DASHBOARD
6.3. MARKET SIZE & FORECASTS TREND ANALYSIS, 2025 TO 2033:
6.4. NORTH AMERICA
6.4.1. NORTH AMERICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS, BY COUNTRY,
6.4.2. U.S.
6.4.2.1. KEY COUNTRY DYNAMICS
6.4.2.2. REGULATORY FRAMEWORK
6.4.2.3. COMPETITIVE INSIGHTS
6.4.2.4. U.S. ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.4.3. CANADA
6.4.3.1. KEY COUNTRY DYNAMICS
6.4.3.2. REGULATORY FRAMEWORK
6.4.3.3. COMPETITIVE INSIGHTS
6.4.3.4. CANADA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.4.4. MEXICO
6.4.4.1. KEY COUNTRY DYNAMICS
6.4.4.2. REGULATORY FRAMEWORK
6.4.4.3. COMPETITIVE INSIGHTS
6.4.4.4. MEXICO ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5. EUROPE
6.5.1. EUROPE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS, BY COUNTRY,
6.5.2. UK
6.5.2.1. KEY COUNTRY DYNAMICS
6.5.2.2. REGULATORY FRAMEWORK
6.5.2.3. COMPETITIVE INSIGHTS
6.5.2.4. UK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.3. GERMANY
6.5.3.1. KEY COUNTRY DYNAMICS
6.5.3.2. REGULATORY FRAMEWORK
6.5.3.3. COMPETITIVE INSIGHTS
6.5.3.4. GERMANY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.4. FRANCE
6.5.4.1. KEY COUNTRY DYNAMICS
6.5.4.2. REGULATORY FRAMEWORK
6.5.4.3. COMPETITIVE INSIGHTS
6.5.4.4. FRANCE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.5. ITALY
6.5.5.1. KEY COUNTRY DYNAMICS
6.5.5.2. REGULATORY FRAMEWORK
6.5.5.3. COMPETITIVE INSIGHTS
6.5.5.4. ITALY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.6. SPAIN
6.5.6.1. KEY COUNTRY DYNAMICS
6.5.6.2. REGULATORY FRAMEWORK
6.5.6.3. COMPETITIVE INSIGHTS
6.5.6.4. SPAIN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.7. NORWAY
6.5.7.1. KEY COUNTRY DYNAMICS
6.5.7.2. REGULATORY FRAMEWORK
6.5.7.3. COMPETITIVE INSIGHTS
6.5.7.4. NORWAY ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.8. DENMARK
6.5.8.1. KEY COUNTRY DYNAMICS
6.5.8.2. REGULATORY FRAMEWORK
6.5.8.3. COMPETITIVE INSIGHTS
6.5.8.4. DENMARK ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.5.9. SWEDEN
6.5.9.1. KEY COUNTRY DYNAMICS
6.5.9.2. REGULATORY FRAMEWORK
6.5.9.3. COMPETITIVE INSIGHTS
6.5.9.4. SWEDEN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS, BY COUNTRY,
6.6. ASIA PACIFIC
6.6.1. ASIA PACIFIC ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.6.2. JAPAN
6.6.2.1. KEY COUNTRY DYNAMICS
6.6.2.2. REGULATORY FRAMEWORK
6.6.2.3. COMPETITIVE INSIGHTS
6.6.2.4. JAPAN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.6.3. CHINA
6.6.3.1. KEY COUNTRY DYNAMICS
6.6.3.2. REGULATORY FRAMEWORK
6.6.3.3. COMPETITIVE INSIGHTS
6.6.3.4. CHINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.6.4. INDIA
6.6.4.1. KEY COUNTRY DYNAMICS
6.6.4.2. REGULATORY FRAMEWORK
6.6.4.3. COMPETITIVE INSIGHTS
6.6.4.4. INDIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.6.5. AUSTRALIA
6.6.5.1. KEY COUNTRY DYNAMICS
6.6.5.2. REGULATORY FRAMEWORK
6.6.5.3. COMPETITIVE INSIGHTS
6.6.5.4. AUSTRALIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.6.6. SOUTH KOREA
6.6.6.1. KEY COUNTRY DYNAMICS
6.6.6.2. REGULATORY FRAMEWORK
6.6.6.3. COMPETITIVE INSIGHTS
6.6.6.4. SOUTH KOREA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.6.7. THAILAND
6.6.7.1. KEY COUNTRY DYNAMICS
6.6.7.2. REGULATORY FRAMEWORK
6.6.7.3. COMPETITIVE INSIGHTS
6.6.7.4. THAILAND ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.7. LATIN AMERICA
6.7.1. LATIN AMERICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS, BY COUNTRY,
6.7.2. BRAZIL
6.7.2.1. KEY COUNTRY DYNAMICS
6.7.2.2. REGULATORY FRAMEWORK
6.7.2.3. COMPETITIVE INSIGHTS
6.7.2.4. BRAZIL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.7.3. ARGENTINA
6.7.3.1. KEY COUNTRY DYNAMICS
6.7.3.2. REGULATORY FRAMEWORK
6.7.3.3. COMPETITIVE INSIGHTS
6.7.3.4. ARGENTINA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.8. MEA
6.8.1. MEA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS, BY COUNTRY,
6.8.2. SOUTH AFRICA
6.8.2.1. KEY COUNTRY DYNAMICS
6.8.2.2. REGULATORY FRAMEWORK
6.8.2.3. COMPETITIVE INSIGHTS
6.8.2.4. SOUTH AFRICA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.8.3. SAUDI ARABIA
6.8.3.1. KEY COUNTRY DYNAMICS
6.8.3.2. REGULATORY FRAMEWORK
6.8.3.3. COMPETITIVE INSIGHTS
6.8.3.4. SAUDI ARABIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.8.4. UAE
6.8.4.1. KEY COUNTRY DYNAMICS
6.8.4.2. REGULATORY FRAMEWORK
6.8.4.3. COMPETITIVE INSIGHTS
6.8.4.4. UAE ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
6.8.5. KUWAIT
6.8.5.1. KEY COUNTRY DYNAMICS
6.8.5.2. REGULATORY FRAMEWORK
6.8.5.3. COMPETITIVE INSIGHTS
6.8.5.4. KUWAIT ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ESTIMATES AND FORECASTS,
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. PARTICIPANT OVERVIEW
7.2. COMPANY MARKET POSITION ANALYSIS
7.3. COMPANY CATEGORIZATION
7.4. STRATEGY MAPPING
7.5. COMPANY PROFILES/LISTING
7.5.1. ACCORD HEALTHCARE LTD.
7.5.1.1. OVERVIEW
7.5.1.2. FINANCIAL PERFORMANCE
7.5.1.3. PRODUCT BENCHMARKING
7.5.1.4. STRATEGIC INITIATIVES
7.5.2. ASTELLAS PHARMA, INC.
7.5.2.1. OVERVIEW
7.5.2.2. FINANCIAL PERFORMANCE
7.5.2.3. PRODUCT BENCHMARKING
7.5.2.4. STRATEGIC INITIATIVES
7.5.3. BRISTOL MYERS SQUIBB
7.5.3.1. OVERVIEW
7.5.3.2. FINANCIAL PERFORMANCE
7.5.3.3. PRODUCT BENCHMARKING
7.5.3.4. STRATEGIC INITIATIVES
7.5.4. DR. REDDY’S LABORATORIES
7.5.4.1. OVERVIEW
7.5.4.2. FINANCIAL PERFORMANCE
7.5.4.3. PRODUCT BENCHMARKING
7.5.4.4. STRATEGIC INITIATIVES
7.5.5. F. HOFFMAN LA-ROCHE, LTD.
7.5.5.1. OVERVIEW
7.5.5.2. FINANCIAL PERFORMANCE
7.5.5.3. PRODUCT BENCHMARKING
7.5.5.4. STRATEGIC INITIATIVES
7.5.6. GENZYME CORPORATION
7.5.6.1. OVERVIEW
7.5.6.2. FINANCIAL PERFORMANCE
7.5.6.3. PRODUCT BENCHMARKING
7.5.6.4. STRATEGIC INITIATIVES
7.5.7. GLAXOSMITHKLINE
7.5.7.1. OVERVIEW
7.5.7.2. FINANCIAL PERFORMANCE
7.5.7.3. PRODUCT BENCHMARKING
7.5.7.4. STRATEGIC INITIATIVES
7.5.8. MYLAN LABORATORIES
7.5.8.1. OVERVIEW
7.5.8.2. FINANCIAL PERFORMANCE
7.5.8.3. PRODUCT BENCHMARKING
7.5.8.4. STRATEGIC INITIATIVES
7.5.9. NOVARTIS AG
7.5.9.1. OVERVIEW
7.5.9.2. FINANCIAL PERFORMANCE
7.5.9.3. PRODUCT BENCHMARKING
7.5.9.4. STRATEGIC INITIATIVES
7.5.10. PFIZER
7.5.10.1. OVERVIEW
7.5.10.2. FINANCIAL PERFORMANCE
7.5.10.3. PRODUCT BENCHMARKING
7.5.10.4. STRATEGIC INITIATIVES
7.5.11. ROCHE
7.5.11.1. OVERVIEW
7.5.11.2. FINANCIAL PERFORMANCE
7.5.11.3. PRODUCT BENCHMARKING
7.5.11.4. STRATEGIC INITIATIVES
7.5.12. SANOFI
7.5.12.1. OVERVIEW
7.5.12.2. FINANCIAL PERFORMANCE
7.5.12.3. PRODUCT BENCHMARKING
7.5.12.4. STRATEGIC INITIATIVES
7.5.13. VIATRIS, INC.
7.5.13.1. OVERVIEW
7.5.13.2. FINANCIAL PERFORMANCE
7.5.13.3. PRODUCT BENCHMARKING
7.5.13.4. STRATEGIC INITIATIVES
著作権 ©2022 無断複写・転載を禁じます
